Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 6Terminated 2Recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 37Breast 8Other solid neoplasm 6Genitourinary 6Gastrointestinal 6Head & Neck 5Gynecologic 4Sarcoma 3Dermatologic 3Endocrine 2CNS 2Other neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 5Pheochromocytoma 4Paraganglioma 3Gastro-enteropancreatic neuroendocrine tumor 3Vipoma 2Neoplasms 2Insulinoma 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms, Cystic, Mucinous, and Serous 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Liver Neoplasms 1Hypoglycemia 1Glucagonoma 1Gastrinoma 1Diarrhea 1Carcinoma, Medullary 1Cachexia 1Adrenal Gland Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Small Cell Lung Carcinoma × NET × Clear all
NCT02030184 2019-10-17

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

University of Maryland, Baltimore

Phase 1/2 Withdrawn
EndocrineNETThoracic

Lung Neoplasms, Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡